{"entity":{"id":"nanjing-immunophage-biotech","kind":"company","name":"Nanjing Immunophage Biotech","aka":["Nanjing Immunophage Biotech Co., Ltd"],"tldr":"Nanjing Immunophage Biotech is a Chinese developer in Nanjing that sponsors 2 registered cancer trials of IPG1094 and IPG7236.","summary":"Nanjing Immunophage Biotech appears on ClinicalTrials.gov as the industry sponsor of 2 interventional cancer trials (phase 1/2), testing IPG1094, IPG7236, Toripalimab in solid tumor, advanced solid tumor. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by Nanjing Immunophage Biotech","url":"https://clinicaltrials.gov/search?spons=Nanjing%20Immunophage%20Biotech"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06212076","nct07508761"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"hq":"Nanjing, China","country":"CN","companyType":"biotech","investors":[],"funding":[]},"route":"/companies/nanjing-immunophage-biotech/","neighbours":{"trial":[{"id":"nct07508761","kind":"trial","name":"IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors","route":"/trials/nct07508761/"},{"id":"nct06212076","kind":"trial","name":"Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients","route":"/trials/nct06212076/"}]}}